bioRxiv Science⌕ Search

Biology subjects

Venna, V. R.

Publications and source records attributed to Venna, V. R..

3 recordsLinked to original sources

Neuropathological hallmarks during the chronic phase of ischemic stroke in mice and humans

BackgroundImprovements in acute stroke treatment, including endovascular thrombectomy and critical care management, have increased survival rates post-stroke. However, stroke remains a leading cause of long-term disability and many survivors have significant neurological and cognitive deficits. Despite this, the chronic neurological sequelae and underlying secondary injury mechanisms induced by ischemic stroke remain understudied. MethodsThis study examined long-term neurobehavioral recovery and neuropathology at 2- and 6- months post-stroke in young (12-week-old) male C57Bl/6 mice after a 60-minute transient middle cerebral artery occlusion (MCAO) or sham surgery. Behavioral testing included the open field test (OFT), novel object recognition test (NORT), fear conditioning (FC), nesting activity, and tail suspension. Post-mortem brain samples from patients with chronic ischemic stroke were also assessed. Immunohistochemistry (IHC) was performed to assess demyelination (MBP), neuronal apoptosis (TUNEL), and A{beta}42 in human brains. Flow cytometric analysis was performed to assess microglial phenotypes, the chronic neuroimmune landscape, and to evaluate senescent-like phenotypes (SA-{beta}Gal and lipofuscin). Transcriptomic profiling was performed using RNA isolated from the ipsilateral hemisphere in stroke mice. ResultsExperimental stroke caused progressive cognitive and motor decline up to 6 months post-MCAO. IHC and flow cytometric analyses revealed a significant increase in TUNEL-positive neurons, cortical and hippocampal gliosis, white matter degradation, senescent cell accumulation, and altered microglial function. IHC analysis of postmortem human brains shows significantly increased levels of microgliosis, senescent cells and amyloid burden. Transcriptomic analysis revealed that pathways involving apoptosis, microglial activation and the complement pathway were chronically upregulated after stroke. ConclusionOur findings demonstrate that ischemic stroke induces a non-resolving microglial response and accelerated inflamm-aging in the brain, evidenced by premature senescence and elevated production of cytokines within the chronic infarct microenvironment. Senescent-like phenotypes and chronic neurodegenerative disease signatures may contribute to the progressive worsening of cognitive function post-stroke. These results suggest that chronic, ongoing neurodegeneration occurs late after stroke, even in younger mice. Mitigating these detrimental changes may offer viable targets for delayed treatment strategies for stroke.

neuroscience↗

Mitochondria-containing extracellular vesicles from mouse vs. human brain endothelial cells for ischemic stroke therapy

Ischemic stroke-induced mitochondrial dysfunction in the blood-brain barrier-forming brain endothelial cells (BECs) results in long-term neurological dysfunction post-stroke. We previously data from a pilot study where intravenous administration of human BEC (hBEC)-derived mitochondria-containing extracellular vesicles (EVs) showed a potential efficacy signal in a mouse middle cerebral artery occlusion (MCAo) model of stroke. We hypothesized that EVs harvested from donor species homologous to the recipient species (e.g., mouse) may improve therapeutic efficacy, and therefore, use of mouse BEC (mBEC)-derived EVs may improve post-stroke outcomes in MCAo mice. We investigated potential differences in the mitochondria transfer of EVs derived from the same species as the recipient cell (mBEC-EVs and recipient mBECs or hBECs-EVs and recipient hBECs) vs. cross-species EVs and recipient cells (mBEC-EVs and recipient hBECs or vice versa). Our results showed that while both hBEC- and mBEC-EVs transferred EV mitochondria, mBEC-EVs outperformed hBEC-EVs in increasing ATP levels and improved recipient mBEC mitochondrial function via increasing oxygen consumption rates. mBEC-EVs significantly reduced brain infarct volume and neurological deficit scores compared to vehicle-injected MCAo mice. The superior therapeutic efficacy of mBEC-EVs in a mouse MCAo stroke support the continued use of mBEC-EVs to optimize the therapeutic potential of mitochondria-containing EVs in preclinical mouse models. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=84 SRC="FIGDIR/small/575903v2_ufig1.gif" ALT="Figure 1"> View larger version (28K): org.highwire.dtl.DTLVardef@d1deb4org.highwire.dtl.DTLVardef@74157corg.highwire.dtl.DTLVardef@12eb991org.highwire.dtl.DTLVardef@990a47_HPS_FORMAT_FIGEXP M_FIG C_FIG

bioengineering↗

Popeye Domain-Containing Protein 1 Scaffolds a Complex of Adenylyl Cyclase 9 and the Two-Pore-Domain Potassium Channel TREK-1 in Heart

The establishment of macromolecular complexes by scaffolding proteins such as A-kinase anchoring proteins is key to the local production of cAMP by anchored adenylyl cyclase (AC) and the subsequent cAMP signaling necessary for many cardiac functions. We have identified herein a novel AC scaffold, the Popeye domain-containing (POPDC) protein. Unlike other AC scaffolding proteins, POPDC1 binds cAMP with high affinity. The POPDC family of proteins are important for cardiac pacemaking and conduction, due in part to their cAMP-dependent binding and regulation of TREK-1 potassium channels. TREK-1 binds the AC9:POPDC1 complex and co-purifies in a POPDC1-dependent manner with AC9-associated activity in heart. Although the interaction of AC9 and POPDC1 is cAMP independent, TREK-1 association with AC9 and POPDC1 is reduced in an isoproterenol-dependent manner, requiring an intact cAMP binding Popeye domain and AC activity within the complex. We show that deletion of Adcy9 (AC9) gives rise to bradycardia at rest and stress-induced heart rate variability. The phenotype for deletion of Adcy9 is milder than previously observed upon loss of Popdc1, but similar to loss of Kcnk2 (TREK-1). Thus, POPDC1 represents a novel scaffolding protein for AC9 to regulate heart rate control. ONE-SENTENCE SUMMARYAdenylyl cyclase type 9 binds in an isoproterenol-dependent manner to the POPDC1:TREK-1 complex regulating heart rate.

biochemistry↗